National Bank of Canada FI Decreases Stock Holdings in Stryker Corporation $SYK

National Bank of Canada FI decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 5.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 352,048 shares of the medical technology company’s stock after selling 21,990 shares during the period. National Bank of Canada FI’s holdings in Stryker were worth $139,262,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Stryker by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock worth $13,253,831,000 after buying an additional 440,607 shares during the last quarter. State Street Corp boosted its position in Stryker by 1.0% in the second quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock worth $5,929,765,000 after purchasing an additional 150,204 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the period. Geode Capital Management LLC increased its position in shares of Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after purchasing an additional 79,654 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in shares of Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after purchasing an additional 4,223,366 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.3%

Shares of SYK stock opened at $353.99 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company’s fifty day moving average price is $366.81 and its 200-day moving average price is $378.45. The company has a market capitalization of $135.37 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.Stryker’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio (DPR) is 44.15%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Wells Fargo & Company lifted their price target on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research note on Friday, November 14th. UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Finally, Evercore ISI cut their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $431.83.

Insider Buying and Selling

In other news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares in the company, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 522,118 shares of company stock valued at $185,381,932. Corporate insiders own 5.20% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.